Close Menu

Breaking News

The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.

Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.

The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.

Ethos said Agena's MALDI-TOF-based MassArray system will allow for more rapid and lower-cost detection of SARS-Cov-2 variants than next-generation sequencing.

The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.

The firm said its rapid antigen test provided 97.3 percent sensitivity and 99.6 percent specificity in clinical studies, and it is developing a saliva-based version.

This modular system uses a high-throughput version of the company's Applied Biosystems TaqPath COVID-19 Combo Kit, which received an EUA in March 2020.

The test, which runs on Ortho's Vitros system, was first CE marked in October for use with nasopharyngeal swab specimens and certain viral transport media.

The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.

The pilot program is intended to increase consistency and predictability when determining conformity with consensus standards and test methods.

Last week, readers were most interested in NIH's RADx-UP program to address disparities in COVID-19 testing in underserved communities. 

The company is planning to fund projects for SARS-CoV-2 testing, early disease detection, disease prognostics, and public health genomics projects.

Lucira Health's at-home molecular test received Emergency Use Authorization in November for prescription use.

DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.

The technology underlying the test was developed by Dutch firm Minicare, which was acquired by Siemens in 2019.

The companies began working together in 2018, when MEDx was known as Qiagen Translational Medicine, on companion and in vitro diagnostics.

Novacyt noted that it generated $98.5 million in the first quarter of 2021, about half of which came from sales to the DHSC.

News items for the in vitro diagnostics industry for the week of April 5, 2021.

The three tests run on the firm's Vidas systems and expand the firm's footprint in vector-borne disease.

Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.

CA Healthcare Acquisition, a special purpose acquisition company, said the transaction will support the development of LumiraDx’s pipeline of more than 30 assays.

The immunoassay can be used to monitor cancer cell remnants in a patient's body and help determine which patients need less invasive treatment.

The Israeli-based startup will use the funds to continue development of its EpiCheck methylation platform and to develop the Lung EpiCheck assay.

The company's test uses self-collected saliva samples from potential parents to assess their future child's genetic predisposition to various diseases.

The prescription-only test from Symbiotica is designed to detect immunoglobulin G against SARS-CoV-2 in dried blood spots obtained via fingerstick.